Circassia Pharmaceuticals PLC Company Profile (LON:CIR)

About Circassia Pharmaceuticals PLC (LON:CIR)

Circassia Pharmaceuticals PLC logoCircassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline's (GSK's) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: LON:CIR
  • CUSIP: N/A
  • Web: www.circassia.com/
Capitalization:
  • Market Cap: £239.08 million
  • Outstanding Shares: 284,622,000
Average Prices:
  • 50 Day Moving Avg: GBX 87.40
  • 200 Day Moving Avg: GBX 92.23
  • 52 Week Range: GBX 76.75 - GBX 114
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £23.1 million
  • Price / Sales: 10.35
  • Book Value: GBX 0.99 per share
  • Price / Book: 0.85
Profitability:
  • EBIDTA: ($66,300,000.00)
  • Net Margins: -296.67%
  • Return on Equity: -23.45%
  • Return on Assets: -20.22%
Misc:
  • Average Volume: 276,647 shs.
 

Frequently Asked Questions for Circassia Pharmaceuticals PLC (LON:CIR)

What is Circassia Pharmaceuticals PLC's stock symbol?

Circassia Pharmaceuticals PLC trades on the London Stock Exchange (LON) under the ticker symbol "CIR."

When will Circassia Pharmaceuticals PLC make its next earnings announcement?

Circassia Pharmaceuticals PLC is scheduled to release their next quarterly earnings announcement on Monday, September, 25th 2017. View Earnings Estimates for Circassia Pharmaceuticals PLC.

Where is Circassia Pharmaceuticals PLC's stock going? Where will Circassia Pharmaceuticals PLC's stock price be in 2017?

4 equities research analysts have issued 1-year price targets for Circassia Pharmaceuticals PLC's shares. Their forecasts range from GBX 120 to GBX 180. On average, they expect Circassia Pharmaceuticals PLC's stock price to reach GBX 145 in the next year. View Analyst Ratings for Circassia Pharmaceuticals PLC.

Who are some of Circassia Pharmaceuticals PLC's key competitors?

Who are Circassia Pharmaceuticals PLC's key executives?

Circassia Pharmaceuticals PLC's management team includes the folowing people:

  • Francesco Granata M.D., Non-Executive Chairman of the Board
  • Steven Harris, Chief Executive Officer, Executive Director
  • Julien Cotta, Chief Financial Officer, Executive Director, Company Secretary
  • Rod Hafner, Director and Senior Vice President Research & Development, Executive Director
  • Russell Cummings, Non-Executive Director
  • Jean-Jacques Garaud M.D., Senior Independent Non-Executive Director
  • Marvin S. Samson, Independent Non-Executive Director
  • Lota S. Zoth CPA, Independent Non-Executive Director

How do I buy Circassia Pharmaceuticals PLC stock?

Shares of Circassia Pharmaceuticals PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Circassia Pharmaceuticals PLC's stock price today?

One share of Circassia Pharmaceuticals PLC stock can currently be purchased for approximately GBX 84.


MarketBeat Community Rating for Circassia Pharmaceuticals PLC (LON CIR)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about Circassia Pharmaceuticals PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Circassia Pharmaceuticals PLC (LON:CIR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: GBX 145

Analysts' Ratings History for Circassia Pharmaceuticals PLC (LON:CIR)
Show:
DateFirmActionRatingPrice TargetDetails
9/8/2017J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
9/7/2017Numis Securities LtdReiterated RatingBuyGBX 180View Rating Details
4/26/2017Peel HuntDowngradeHoldGBX 150 -> GBX 130View Rating Details
4/25/2017Stifel NicolausReiterated RatingBuyGBX 150View Rating Details
6/21/2016Barclays PLCInitiated CoverageOverweightGBX 410 -> GBX 170View Rating Details
6/21/2016Royal Bank Of CanadaDowngradeSector PerformerGBX 430 -> GBX 105View Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Circassia Pharmaceuticals PLC (LON:CIR)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Circassia Pharmaceuticals PLC (LON:CIR)
Current Year EPS Consensus Estimate: $-23.18 EPS

Dividends

Dividend History for Circassia Pharmaceuticals PLC (LON:CIR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Circassia Pharmaceuticals PLC (LON:CIR)
Insider Trades by Quarter for Circassia Pharmaceuticals PLC (LON:CIR)
Insider Trades by Quarter for Circassia Pharmaceuticals PLC (LON:CIR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/2/2017Jean-Jacques GaraudInsiderSell77,500GBX 89£68,975
9/18/2015Swingland,CharlesInsiderSell754,548GBX 320£2,414,553.60
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Circassia Pharmaceuticals PLC (LON:CIR)
Latest Headlines for Circassia Pharmaceuticals PLC (LON:CIR)
Source:
DateHeadline
finance.yahoo.com logoShould You Buy Circassia Pharmaceuticals Plc (LSE:CIR) Now?
finance.yahoo.com - September 15 at 5:35 PM
morningstar.co.uk logoCircassia Pharma Launches Nasal Screening NIOX VERO In Europe
www.morningstar.co.uk - September 12 at 5:50 PM
americanbankingnews.com logoCircassia Pharmaceuticals PLC's (CIR) "Buy" Rating Reaffirmed at Numis Securities Ltd
www.americanbankingnews.com - September 10 at 10:50 AM
americanbankingnews.com logoJ P Morgan Chase & Co Reiterates Neutral Rating for Circassia Pharmaceuticals PLC (CIR)
www.americanbankingnews.com - September 9 at 8:18 PM
lse.co.uk logoTOP NEWS: AstraZeneca Sees Positive Duaklir, Tezepelumab Study Results - London South East (registration) (blog)
www.lse.co.uk - September 9 at 4:54 PM
morningstar.co.uk logoUPDATE: AstraZeneca Says Imfinzi Trials Placed On Hold By US FDA
www.morningstar.co.uk - September 7 at 10:23 PM
streetinsider.com logoCircassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease
www.streetinsider.com - September 7 at 3:22 AM
marketwatch.com logoAstraZeneca's Duaklir trial hits primary endpoints
www.marketwatch.com - September 7 at 3:22 AM
finance.yahoo.com logoCircassia Announces Duaklir(R) Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease
finance.yahoo.com - September 7 at 3:22 AM
ft.com logoWoodford dented after AstraZeneca and Provident shares fall - Financial Times
www.ft.com - July 31 at 2:34 AM
americanbankingnews.com logoCircassia Pharmaceuticals PLC (CIR) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 12 at 7:32 AM
americanbankingnews.com logoJean-Jacques Garaud Sells 77,500 Shares of Circassia Pharmaceuticals PLC (CIR) Stock
www.americanbankingnews.com - June 6 at 7:16 AM
americanbankingnews.com logoCircassia Pharmaceuticals PLC (CIR) Stock Rating Reaffirmed by JPMorgan Chase & Co.
www.americanbankingnews.com - May 28 at 7:49 AM
americanbankingnews.com logoCircassia Pharmaceuticals PLC (CIR) Earns "Buy" Rating from Numis Securities Ltd
www.americanbankingnews.com - May 26 at 7:14 AM
americanbankingnews.com logoCircassia Pharmaceuticals PLC (CIR) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 16 at 9:46 AM
finance.yahoo.com logoCircassia Pharmaceuticals Plc – Value Analysis (LONDON:CIR) : May 12, 2017
finance.yahoo.com - May 12 at 9:54 PM
finance.yahoo.com logoCircassia Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : CIR-GB : May 11, 2017
finance.yahoo.com - May 11 at 4:57 PM
reuters.com logoBRIEF-Circassia Pharmaceuticals fy revenues increased to 23.1 mln stg
www.reuters.com - April 26 at 9:50 PM
finance.yahoo.com logo[$$] Circassia losses at widen after failed clinical trials
finance.yahoo.com - April 26 at 9:50 PM
americanbankingnews.com logoStifel Nicolaus Reiterates Buy Rating for Circassia Pharmaceuticals PLC (CIR)
www.americanbankingnews.com - April 25 at 7:07 AM
americanbankingnews.com logoCircassia Pharmaceuticals PLC (CIR) Rating Reiterated by JPMorgan Chase & Co.
www.americanbankingnews.com - April 23 at 9:56 PM
americanbankingnews.com logoCircassia Pharmaceuticals PLC (CIR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 21 at 9:53 AM
morningstar.co.uk logoCircassia Gets Early Termination Of Waiting Period In AstraZeneca Deal
www.morningstar.co.uk - April 11 at 11:24 AM
americanbankingnews.com logoCircassia Pharmaceuticals PLC (CIR) Earns "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - April 8 at 6:08 PM
americanbankingnews.com logoCircassia Pharmaceuticals PLC (CIR) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 27 at 1:50 PM
americanbankingnews.com logoCircassia Pharmaceuticals PLC's (CIR) "Neutral" Rating Reaffirmed at JPMorgan Chase & Co.
www.americanbankingnews.com - March 24 at 4:21 AM
americanbankingnews.com logoCircassia Pharmaceuticals PLC (CIR) Upgraded by Stifel Nicolaus to "Buy"
www.americanbankingnews.com - March 20 at 12:34 PM
americanbankingnews.com logoCircassia Pharmaceuticals PLC (CIR) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 17 at 9:06 PM
bloomberg.com logoWoodford-Backed Biopharma Stock Circassia Surges on Astra Pact
www.bloomberg.com - March 17 at 3:47 PM
bizjournals.com logo$230M deal: AstraZeneca forms COPD drugs collaboration
www.bizjournals.com - March 17 at 3:47 PM
finanznachrichten.de logoINVESCO PERPETUAL SELECT TRUST PLC - Half-year Report
www.finanznachrichten.de - February 1 at 4:38 PM
lse.co.uk logoTotal Voting Rights Update - London South East (registration) (blog)
www.lse.co.uk - December 1 at 4:28 PM
reuters.com logoUK Stocks-Factors to watch on Sept. 27
www.reuters.com - September 27 at 8:49 AM
biz.yahoo.com logoHalf Year 2016 Circassia Pharmaceuticals PLC Earnings Release - Time Not Supplied
biz.yahoo.com - September 27 at 8:49 AM

Social

Social activity is not available for this stock.

Chart

Circassia Pharmaceuticals PLC (CIR) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff